Douglas R. Adkins, MD

Douglas R. Adkins, MD

Professor

Address:
Division of Oncology
Mail Stop 8056-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110

11th Floor Mid Campus Center (office)

Admin:
Ebony McGee
ebonyvmcgee@wustl.edu

Clinical Interests
  • Head and neck cancer
  • Thyroid cancer
Research: Areas of Clinical Research Interest
  • Head and Neck Cancer
    • 1. CDK4/6 inhibitors
    • 2. Immunotherapy
    • 3. VEGFR inhibitors
    • 4. EZH2 inhibitors
    • 5. PARP inhibitors
    • 6. Nanoparticle albumin-bound paclitaxel
    • 7. EGFR, Her-3 and MTOR inhibitors
  • Thyroid Cancer
    • 1. Targeted agents in the treatment of medullary, differentiated and anaplastic thyroid cancers

Current Research Projects

  • Head and Neck Cancer
    • 1. A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    • 2. Los Tres PasosTrial: Step One – Neoadjuvant Palbociclib Monotherapy, Step Two – Concurrent Chemoradiation Therapy, and Step Three – Adjuvant Palbociclib Monotherapy in Patients with p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
    • 3. Pembrolizumab (MK-3475) in locoregionally advanced, surgically resectable HPV-Unrelated head and neck squamous cell carcinoma
    • 4. Tazemetostat and Pembrolizumab in Patients with Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
    • 5. Olaparib in Combination with Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
    • 6. Nab-Paclitaxel + Nivolumab for HNSCC that Progressed on a PD-1 Inhibitor: A Single-Arm, Phase 2 Trial
    • 7. Participation in cooperative group (RTOG, ECOG, SWOG, P2C), pharmaceutical and multi-institutional investigator initiated clinical trials in SCCHN
  • Thyroid Cancer
    • 1. Participation in cooperative group (P2C, Alliance) and pharmaceutical clinical trials in thyroid cancer: 17-AAG (P2C), Zactima, Sorafenib, XL184/Cabozantinib (Exelixis), CS-7017 (Daiichi Sankyo Pharma), Pazopanib (P2C), Cediranib/Lenalidomide (P2C), Efatutazone (Alliance), LOXO-292/Selpercatinib (Lilly), BLU-667/Pralsetinib (Blue)
Profiles (publications)
WU Physician Bio

Biosketch

Education

  • 1986: MD, Wright State University School of Medicine, Dayton, OH
  • 1982: BS in Biological Sciences (summa cum laude), Wright State University, Dayton, OH

Post-Graduate Training

  • 1992-1990: Fellowship, Bone Marrow Transplantation, University of Texas Health Sciences Center, San Antonio, TX
  • 1990-1989: Fellowship, Medical Oncology/Hematology, University of Texas Health Sciences Center, San Antonio, TX
  • 1989-1986: Internship & Residency, Internal Medicine, University of Texas Health Sciences Center, San Antonio, TX

Academic Positions

  • present-2012: Professor of Medicine, Washington University School of Medicine, St. Louis, MO
  • 2019-2011: Director, Hematology and Medical Oncology Fellowship Program, Washington University School of Medicine, St. Louis, MO
  • 2018-2008: Primary Institutional Investigator, Washington University Mayo Clinic Phase II Consortium
  • 2012-2002: Associate Professor of Medicine, Washington University School of Medicine, St. Louis, MO
  • 2004-1995: Medical Director, National Marrow Donor Program Transplant and Collection Center, Washington University School of Medicine, Division of Oncology, St. Louis, MO
  • 2003-1998: Supervisor, Data Management Section, Washington University School of Medicine, Division of Oncology, St. Louis, MO
  • 1994-1992: Director, Allogeneic Bone Marrow Transplant Program and Medical Director, National Marrow Donor Program Transplant/Collection Center, Division of Bone Marrow Transplantation, Oncology & Hematology, Saint Louis University Health Sciences Center, St. Louis, MO
  • 1994-1992: Assistant Professor of Medicine, Division of Bone Marrow Transplantation, Oncology & Hematology, Saint Louis University Health Sciences Center, St. Louis, MO
  • 2002-1995: Assistant Professor of Medicine, Washington University School of Medicine, St. Louis, MO

Committees

  • present-2021: Chair, Standing Data Safety and Monitoring Board, Siteman Cancer Center
  • present-2020: Chair, BJH Pharmacy & Therapeutics Committee, Siteman Cancer Center & Washington University School of Medicine
  • present-2017: High Cost Medication Committee, Siteman Cancer Center & Washington University School of Medicine
  • present-2015: NCI Head and Neck Steering Committee
  • present-2012: Siteman Cancer Center Clinical Trials Working Group
  • present-2004: Head & Neck Cancer Focus Research Group, Siteman Cancer Center & Washington University School of Medicine
  • 2021-2016: NCI Metastatic and Recurrent Head & Neck Cancer Task Force
  • 2016-2015: Otolaryngology Search Committee, Washington University School of Medicine
  • 2003-1998: Clinical Effectiveness Program – BMT Working Group, Barnes-Jewish Hospital & Washington University School of Medicine
  • 2003-1997: Protocol Quality Assurance Committee, Siteman Cancer Center, Washington University School of Medicine
  • 2003-1996: Barnard Cancer Center Physician’s Advisory Board, Washington University School of Medicine
  • 2003-1996: Protocol Review Committee, Division of BMT & Stem Cell Biology, Washington University School of Medicine
  • 2003-1995: Bone Marrow Transplant Unit QA/QI Committee, Barnes Hospital, Washington University School of Medicine
  • 1996-1995: Mucositis Committee: Standards for Grading/Guidelines for Treatment, Barnes Hospital/Washington University School of Medicine
  • 1994-1993: Leukemia Committee, Southwest Oncology Group
  • 1994-1993: Working Group on Medical Records, Saint Louis University Medical Center

Board Certification

  • 1993: Medical Oncology
  • 1990: Internal Medicine

Honors & Awards

  • present-2003: Best Doctors in America
  • 2012: Fellow Teacher of the Year Award
  • 2012: Distinguished Clinician Award Nomination, October 2011
  • 1995: Recipient, Dinah Kukes Grant, Phi Mu Foundation
  • 1992: Recipient, American Society of Clinical Oncology Travel Grant
  • 1989: American Cancer Society Clinical Oncology Fellowship Recipient
  • 1985 Alpha Omega Alpha
  • 1984: Academy of Medicine Award, Wright State University School of Medicine
  • 1984: Montgomery County Medical Society Auxiliary Internal Medicine Scholarship
  • 1983: Miami Valley Family Practice Association Scholarship
  • 1982: Departmental Honors, Biological Sciences
  • 1982: Montgomery County Medical Society Auxiliary Internal Medicine Scholarship

Contributions

  • American Board of Internal Medicine: Contributor to the Recertification Program
  • Council Member: Council on Education and Standards, Task Force on Guidelines for Clinical Centers and Training
  • American Meeting for Blood and Marrow Transplantation, ASBMT Council Report, 2001
  • Clinical Mentor: Lucille P. Markey Special Emphasis Pathway in Human Pathobiology, Washington University School of Medicine
  • National Comprehensive Cancer Network: Bone Cancer Panel Member (past member)
  • National Comprehensive Cancer Network: Head & Neck Cancer Panel Member
  • National Cancer Institute: Head and Neck Steering Committee and Focus Group Member, Metastatic and Recurrent Head and Neck Cancer Task Force (2015-2021)

Professional Societies

  • American Society of Clinical Oncology
  • International Society for Hematotherapy and Graft Engineering
  • International Society for Experimental Hematology
  • American Society of Hematology
  • American Society for Blood and Marrow Transplantation
  • American College of Physicians, Fellow
  • National Marrow Donor Program
  • Texas Medical Association
  • National Cancer Institute Investigator
  • CALGB Investigator
  • St. Louis Metropolitan Medical Society
  • ECOG-ACRIN Cancer Research Group, Scientific Member
  • CTEP Investigator
  • NSABP Member